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Describe role of Submitting/Presenting Trainee in this project (limit 150 words):
Performed a retrospective chart review of patients enrolled under the current IRB project.
Reviewed current literature in both Gastroenterology and Rheumatology with regards to use of
methotrexate polyglutamates as a tool for therapeutic response, therapeutic drug monitoring, and
drug compliance. Participated in data analysis and interpretation and preparation of the
manuscript stemming from this work. Next steps include writing a research protocol for a larger,
longitudinal study aimed at investigating the role of methotrexate polyglutamates monitoring in
treatment response to methotrexate therapy in IBD and JIA.
Background, Objectives/Goal, Methods/Design, Results, Conclusions limited to 500 words
Background:
Methotrexate (MTX) is an immunomodulator used for the treatment of inflammatory bowel disease
(IBD) and juvenile idiopathic arthritis (JIA). After administration, inside blood cells, methotrexate
undergoes addition of glutamate to form methotrexate polyglutamates (MTX-Glu), classified based
on the number (n) of the glutamate side-chains with up to six glutamates (MTX-Glun). MTX-Glu
show promise as potential biomarkers of systemic exposure to MTX and may have clinical utility
for prediction of therapeutic response.
Objectives/Goal:
The aim of this investigation was to compare MTX-Glu disposition in IBD vs. JIA. The clinical utility
of MTX-Glu is being explored in adult rheumatology and gastroenterology literature, with sparse
information in pediatric literature. Our goal was to assess the relationship between MTX-Glu and
therapeutic response in children receiving MTX for IBD and JIA.
Methods/Design:
Cross sectional study of 27 children (5-21 years; 45% female) with IBD or JIA, receiving
combination maintenance therapy with infliximab (IFX) and MTX. At the time of MTX-Glu
measurements in erythrocytes (HPLC/MS), IFX serum trough concentrations were measured by an

established gene-reporter assay (ARUP Laboratories), and disease activity (Remission vs. Active)
determined via 1) agreement on Physician Global Assessment by two pediatric gastroenterologist
for IBD, or 2) JADAS-71 score for JIA, with scores >3.8 indicative of active disease. Given the
variability in clinically prescribed drug dosing, and age and size of children, all data were adjusted
(adj) for mg/kg drug received and interval since drug administration. Spearman’s correlation (ρ),
Wilcoxon Rank Sum tests, and multivariable logistic regression analyses were used to compare
parameters of interest in children with Remission vs. Active Disease (SAS; α<0.05). Unless
otherwise specified, data are reported as Median (Interquartile Range).
Results:
For patients with IBD (90% Crohn’s disease), Total adjMTX-Glu was significantly higher in
Remission [211 (126, 299), n=9) vs. Active Disease [126 (62, 212), n=10], p=0.03. adjMTX-Glu1 [109
(53, 120) vs. 37 (0, 50), p=0.008] and adjMTX-Glu2 [62 (39, 72) vs. 24 (13, 38), p=0.01] were also
significantly higher in Remission vs. Active Disease, with the two study groups comparable for age
and disease duration (both p=0.9). Controlling for IFX dose, interval and trough level in a
multivariable logistic regression, differences in MTX-Glu between Remission and Active Disease
remained significant for adjMTX-Glu1 and adjMTX-Glu2 (short chain MTX-Glu; p≤0.04) and
approached significance for Total adjMTX-Glu (p=0.06). For patients with JIA, no statistically
significant differences were noted in Total adjMTX-Glu, or individual short chain or long chain
(adjMTX-Glu3, 4, 5) MTX-Glu in Remission (n=5) vs. Active Disease (n=3).
Conclusions:
Adjusted for mg/kg MTX received, total and short chain MTX-Glu were significantly higher in
patients with IBD in disease remission vs. active disease, independent of age, disease duration, or
IFX dose, interval or trough, suggesting that MTX-Glu may be important determinants of disease
response to MTX. We did not observe differences in dose-adjusted MTX-Glu in children with JIA in
disease remission vs. active disease; however, this may be secondary to small sample size (n=8).
Larger longitudinal studies of MTX-Glu in MTX mono- and combo-therapy are indicated in pediatric
autoimmune disorders.

